Actiphage is a new laboratory diagnostic for latent tuberculosis to determine who will progress to active disease
Better tests for the diagnosis of latent tuberculosis infection to improve the identification of individuals who are at the greatest risk of developing active tuberculosis are needed. Diagnostics laboratories are instrumental to the fight against TB and need novel diagnostic techniques to identify and isolate Mycobacterium tuberculosis (Mtb) the causative agent.
At the AACC Clinical Lab Expo, PBD Biotech will be showcasing Actiphage®, a phage-based test that identifies Mtb in the blood – an early indication of ‘active’ TB disease. It has potential applications in latent TB screening and drug management.
Actiphage offers phage-based DNA extraction which, when combined with polymerase chain reaction, detects low levels of viable Mtb in blood.
Actiphage featured in AACC webinar
Phage-Based Laboratory Diagnostics Role in the Detection of Tuberculosis
Sponsored by PBD Biotech
Drs Pranab Haldar and Tony Hu discuss the epidemiology of tuberculosis and limitations of current tests that look at host response.
Learn more about how phage-based diagnostic technology can be used to detect incipient and active TB with the AACC webinar – it is available free to view.
About PBD Biotech
PBD Biotech is a clinical-stage diagnostic company and pioneer in phage-based diagnostics. We are focused on the development of Actiphage for the detection of tuberculosis in latent TB screening and drug management and actively seeking partners to support Actiphage research and development.
See us on booth #4578
See us on booth #4578 in the Clinical Lab Expo – to claim your complimentary Clinical Lab Expo pass and join your community for clinical laboratory science education, problem-solving and networking at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo contact us for the promo code.
*A Novel, High-sensitivity, Bacteriophage-based Assay Identifies Low-level Mycobacterium tuberculosis Bacteremia in Immunocompetent Patients With Active and Incipient Tuberculosis Verma et al. Clin Infect Dis. 2020 Feb 14;70(5):933-936. doi: 10.1093/cid/ciz548. PMID: 31233122. See more information.